Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:28:02.501Z.
Calculation as of: 2026-10-06T21:28:02.501Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6423558485129ce458f63e69d797580679928a9eb272818a894d3cfd838ee462
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$4.40M
EV/EBIT Ratio
N/A
TTM Avg
661.60x
3Y Avg
661.60x
5Y Avg
661.60x
Market Cap
$4.21M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.53M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | N/A | 661.60x | 661.60x | 661.60x |
| CalciMedica, Inc. (CALC)vs › | $4.69M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | N/A | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute